Synergistic effects of the polymorphisms in the PAI-1 and IL-6 genes with smoking in determining their associated risk with coronary artery disease

Clinical Biochemistry

Volumn 41, Issue 7-8, 2008, Pages 467-473

  Sarecka, Beata ^a   Zak, Iwona ^a   Krauze, Jolanta ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Coronary artery disease; PAI 1, IL 6; Polymorphisms; Smoking

Indexed keywords

INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOKING;

ADOLESCENT; ADULT; ALLELES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING;

EID: 41849119426     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.01.028     Document Type: Article

References (36)

1. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
2. Nilsson J., Hansson G.K., and Shah P.K. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol 25 (2005) 18-28
3. Castell J.V., Gomez-Lechon M.J., David M., et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 242 (1989) 237-239
4. Keller E.T., Wanagat J., and Ershler W.B. Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci 1 (1996) 340-357
5. Mohamed-Ali V., Goodrick S., Rawesh A., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82 (1997) 4196-4200
6. Fishman D., Faulds G., Jeffery R., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102 (1998) 1369-1376
7. Swiatkiewicz A., Jurkowski P., Kotschy M., Ciecierski M., and Jawien A. Level of antithrombin III, protein C, protein S and other selected parameters of coagulation and fibrinolysis in the blood of the patients with recurrent deep venous thrombosis. Med Sci Monit 8 (2002) 263-268
8. Thogersen A.M., Jansson J.H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
9. Dawson S.J., Wiman B., Hamsten A., Green F., Humphries S., and Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268 (1993) 10739-10745
10. Rega G., Kaun C., Weiss T.W., et al. Inflammatory cytokines interleukin-6 and oncostatin M induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 111 (2005) 1938-1945
11. Dong J., Fujii S., Li H., et al. Interleukin-6 and mevastatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-delta. Arterioscler Thromb Vasc Biol 25 (2005) 1078-1084
12. Dong J., Fujii S., Imagawa S., et al. IL-1 and IL-6 induce hepatocyte plasminogen activator inhibitor-1 expression through independent signaling pathways converging on C/EBPdelta. Am J Physiol Cell Physiol 292 (2007) C209-C215
13. Schuringa J.J., Jonk L.J., Dokter W.H., et al. Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components. Biochem J 347 (2000) 89-96
14. Alpert J.S., and Thygesen K. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J 21 (2000) 1502-1513
15. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of preparative centrifuge. Clin Chem 18 (1972) 499-502
16. Sans M., Tassies D., Pellise M., et al. The 4G/4G genotype of the 4G/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn's disease. Aliment Pharmacol Ther 17 (2003) 1039-1047
17. Elghannam H., Tavackoli S., Ferlic L., Gotto Jr. A.M., Ballantyne C.M., and Marian A.J. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med 78 (2000) 562-568
18. Khoury M.J., and Flanders W.D. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls!. Am J Epidemiol 144 (1996) 207-213
19. Hindorff L.A., Schwartz S.M., Siscovick D.S., Psaty B.M., Longstreth Jr. W.T., and Reiner A.P. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk 9 (2002) 131-137
20. Yamada Y., Izawa H., Ichihara S., et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 347 (2002) 1916-1923
21. Boekholdt S.M., Bijsterveld N.R., Moons A.H., Levi M., Buller H.R., and Peters R.J. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 104 (2001) 3063-3068
22. Juhan-Vague I., Morange P.E., Frere C., et al., HIFMECH Study Group. The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. J Thromb Haemost 1 (2003) 2322-2329
23. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 107 (2003) 1117-1122
24. Ding J., Nicklas B.J., Fallin M.D., et al. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J 152 (2006) 1109-1115
25. Bastard J.P., and Pieroni L. Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity. Biomed Pharmacother 53 (1999) 455-461
26. Margaglione M., Cappucci G., d'Addedda M., et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 18 (1998) 562-567
27. Grancha S., Estelles A., Tormo G., et al. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 81 (1999) 516-521
28. Zak I., Balcerzyk A., Sarecka B., Niemiec P., Ciemniewski Z., and Dylag S. Contemporaneous carrier-state of two or three "proatherosclerotic" variants of APOE, ICAM1, PPARA and PAI-1 genes differentiate CAD patients from healthy individuals. Clin Chim Acta 362 (2005) 110-118
29. Fernandez-Real J.M., Broch M., Vendrell J., Richart C., and Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 85 (2000) 1334-1339
30. Rein T., Forster R., Krause A., Winnacker E.L., and Zorbas H. Organization of the alphaglobin promoter and possible role of nuclear factor I in an alpha-globin-inducible and a noninducible cell line. J Biol Chem 270 (1995) 19643-19650
31. Jones K.G., Brull D.J., Brown L.C., et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 103 (2001) 2260-2265
32. Humphries S.E., Luong L.A., Ogg M.S., Hawe E., and Miller G.J. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 22 (2001) 2243-2252
33. Nauck M., Winkelmann B.R., Hoffmann M.M., Bohm B.O., Wieland H., and Marz W. The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction. J Mol Med 80 (2002) 507-513
34. Sie M.P., Sayed-Tabatabaei F.A., Oei H.H., et al. Interleukin 6 -174 g/c promoter polymorphism and risk of coronary heart disease: results from the Rotterdam study and a meta-analysis. Arterioscler Thromb Vasc Biol 26 (2006) 212-217
35. Bazzano L.A., He J., Muntner P., Vupputuri S., and Whelton P.K. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 138 (2003) 891-897
36. Mazzone A., Cusa C., Mazzucchelli I., et al. Cigarette smoking and hypertension influence nitric oxide release and plasma levels of adhesion molecules. Clin Chem Lab Med 39 (2001) 822-826